PortfoliosLab logo
Biora Therapeutics Inc (BIOR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US74319F1075

IPO Date

Jun 19, 2020

Highlights

Market Cap

$994.99K

EPS (TTM)

$0.36

PE Ratio

0.61

Total Revenue (TTM)

$350.00K

Gross Profit (TTM)

$240.00K

EBITDA (TTM)

-$12.92M

Year Range

$0.15 - $7.90

Target Price

$34.00

Short %

8.58%

Short Ratio

2.37

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Biora Therapeutics Inc

Popular comparisons:
BIOR vs. GGR
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

Biora Therapeutics Inc (BIOR) returned 0.00% year-to-date (YTD) and -96.56% over the past 12 months.


BIOR

YTD

0.00%

1M

0.00%

6M

-89.00%

1Y

-96.56%

3Y*

-89.68%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.92%

1M

4.38%

6M

-1.84%

1Y

12.48%

3Y*

13.05%

5Y*

13.71%

10Y*

10.99%

*Annualized

Monthly Returns

The table below presents the monthly returns of BIOR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20250.00%0.00%0.00%0.00%0.00%0.00%0.00%
2024-30.37%39.36%-16.03%-40.45%-2.29%3.12%1.52%4.03%-27.98%-31.67%-43.15%-88.72%-98.37%
202326.36%-26.62%-9.48%-12.27%84.36%-14.06%-0.52%-22.45%-26.94%-10.37%-36.25%8.87%-59.09%
2022-31.58%-5.59%-14.07%-27.84%0.36%-16.67%-0.00%3.14%-32.83%-21.44%-35.70%-46.12%-93.68%
202129.57%-20.49%-12.98%-33.61%-18.04%37.84%-36.97%-60.44%70.79%136.84%-13.06%-33.23%-60.64%
2020-31.40%1.22%1.32%-2.28%-44.68%-19.64%32.42%-59.53%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BIOR is 4, meaning it’s performing worse than 96% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BIOR is 44
Overall Rank
The Sharpe Ratio Rank of BIOR is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of BIOR is 11
Sortino Ratio Rank
The Omega Ratio Rank of BIOR is 00
Omega Ratio Rank
The Calmar Ratio Rank of BIOR is 11
Calmar Ratio Rank
The Martin Ratio Rank of BIOR is 1010
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Biora Therapeutics Inc (BIOR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Biora Therapeutics Inc Sharpe ratios as of Jun 3, 2025 (values are recalculated daily):

  • 1-Year: -0.93
  • All Time: -0.62

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Biora Therapeutics Inc compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Biora Therapeutics Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Biora Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Biora Therapeutics Inc was 99.99%, occurring on Dec 30, 2024. The portfolio has not yet recovered.

The current Biora Therapeutics Inc drawdown is 99.99%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.99%Jun 22, 20201139Dec 30, 2024
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Biora Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Biora Therapeutics Inc, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -30.9%.


-150.00-100.00-50.000.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJuly
-5.04
-3.85
Actual
Estimate

Valuation

The Valuation section provides an overview of how Biora Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for BIOR, comparing it with other companies in the Biotechnology industry. Currently, BIOR has a P/E ratio of 0.6. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BIOR relative to other companies in the Biotechnology industry. Currently, BIOR has a P/S ratio of 0.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BIOR in comparison with other companies in the Biotechnology industry. Currently, BIOR has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items